Immune evasion is an emerging hallmark of cancer progression. However, functional studies to understand the role of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment are limited by the lack of available specific cell surface markers. We adapted a competitive peptide phage display platform to identify candidate peptides binding MDSCs specifically and generated peptide-Fc fusion proteins (peptibodies). In multiple tumor models, intravenous peptibody injection completely depleted blood, splenic and intratumoral MDSCs in tumor-bearing mice without affecting proinflammatory immune cell types, such as dendritic cells. Whereas control Gr-1-specific antibody primarily depleted granulocytic MDSCs, peptibodies depleted both granulocytic and monocytic MDSC subsets. Peptibody treatment was associated with inhibition of tumor growth in vivo, which was superior to that achieved with Gr-1-specific antibody. Immunoprecipitation of MDSC membrane proteins identified S100 family proteins as candidate targets. Our strategy may be useful to identify new diagnostic and therapeutic surface targets on rare cell subtypes, including human MDSCs.
t e c h n i c a l r e p o r t s
Immune evasion is an emerging hallmark of cancer progression. However, functional studies to understand the role of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment are limited by the lack of available specific cell surface markers. We adapted a competitive peptide phage display platform to identify candidate peptides binding MDSCs specifically and generated peptide-Fc fusion proteins (peptibodies). In multiple tumor models, intravenous peptibody injection completely depleted blood, splenic and intratumoral MDSCs in tumor-bearing mice without affecting proinflammatory immune cell types, such as dendritic cells. Whereas control Gr-1-specific antibody primarily depleted granulocytic MDSCs, peptibodies depleted both granulocytic and monocytic MDSC subsets. Peptibody treatment was associated with inhibition of tumor growth in vivo, which was superior to that achieved with Gr-1-specific antibody. Immunoprecipitation of MDSC membrane proteins identified S100 family proteins as candidate targets. Our strategy may be useful to identify new diagnostic and therapeutic surface targets on rare cell subtypes, including human MDSCs.
Activating the immune system has emerged as a promising way to treat cancer. Recent successful phase 3 clinical trials of therapeutic cancer vaccines include the US Food and Drug Administrationapproved Sipuleucel-T prostate cancer vaccine, melanoma peptide vaccines and personalized lymphoma vaccines [1] [2] [3] . However, tumorinduced immune suppression limits their potency. MDSCs are heterogeneous cells that coexpress Gr-1 and CD11b myeloid lineage differentiation markers [4] [5] [6] . Functional studies have shown that MDSCs are potent inhibitors of T cells in mice [7] [8] [9] [10] , but more specific surface markers that would allow isolation of viable MDSCs would facilitate additional studies to precisely understand tumor-MDSC interactions in the microenvironment. New specific markers are also needed for targeting MDSCs in vivo to test the hypothesis that MDSC inhibition enhances antitumor immunity 4, 10 .
RESULTS

Identification of mouse MDSC-binding peptides
MDSC frequency is low in naive C57BL/6 mice; however, after transplantation of syngeneic EL4 thymomas MDSC numbers are increased, accounting for approximately 10% of total splenocytes 5 . Splenic MDSCs from EL4-bearing mice consist of two distinct subpopulations characterized by Gr-1 high CD11b + granulocytic (P7) and Gr-1 int CD11b + monocytic (P10) staining (Fig. 1a) . With the goal of selecting peptide ligands that specifically bound MDSCs by phage display, we separated Gr-1 + CD11b + MDSCs from non-MDSCs by cell sorting after incubation with a Ph.D.-12 peptide phage library. Phages eluted from granulocytic or monocytic MDSCs were then expanded through rounds of competitive biopanning. We analyzed enrichment by the number of phage eluted from 1 × 10 6 MDSCs (Fig. 1b) and by phage output normalized to the initial input of 2 × 10 10 phages (Fig. 1c) .
Sequencing of enriched phages revealed overrepresented peptide sequences, and two predominant peptides (H6 and G3) were selected for further study ( Table 1) . Each clone that was expanded and tested for binding to MDSCs revealed the specificity of both H6 and G3 phage for MDSCs, without significant binding to non-MDSCs (data not shown). We isolated additional candidate MDSC-binding phages but did not give them further consideration because their binding was not specific. Corresponding synthetic FITC-conjugated H6 and G3 peptides bound specifically to Gr-1 + CD11b + MDSCs but not Gr-1 − CD11b − non-MDSC splenocytes from EL4-bearing mice (Fig. 1d) .
Generation of MDSC-specific peptibodies
We genetically fused sequences encoding H6 and G3 peptides with a sequence encoding the Fc portion of mouse IgG2b to generate peptibodies (Pep-H6 and Pep-G3, respectively) (Fig. 2a) . We also made control peptibodies (Pep-irrel) using nonspecific sequences. Then we produced recombinant peptibodies from 293T human embryonic kidney cells, followed by purification of the peptibodies by protein A chromatography and characterization by western blotting with anti-mouse IgG and anti-His tag antibodies (Fig. 2b) . These peptibodies were conjugated with FITC and analyzed for binding specificity on CD11b + Ly6G − Ly6C high monocytic MDSCs and CD11b + Ly6G + Ly6C int/low granulocytic MDSCs from EL4-bearing mice. Gating on these well-defined subpopulations, we found that Pep-H6 and Pep-G3 bound both monocytic and granulocytic MDSCs ( Fig. 2c and Supplementary Fig. 1a) . However, expression of the Pep-G3 target seemed to be lower in granulocytic MDSCs than in monocytic MDSCs.
Aside from EL4 thymomas, peptibodies stained splenic MDSCs from mice bearing EG.7 thymoma, B16 melanoma and A20 lymphoma ( Fig. 2d and Supplementary Fig. 1b) . Neither peptibody stained Ly6G − CD11c + dendritic cells (DCs), also of myeloid origin (Fig. 2e) . Furthermore, peptibodies did not bind lymphocytes, including B, T and natural killer (NK) cells (Pep-G3 bound a small proportion of T and NK cells) (Supplementary Fig. 2 ). However, we observed specific staining of Gr-1 + CD11b + immature myeloid cells in bone marrow with peptibodies in EL4-bearing mice (Fig. 2f) . Co-staining MDSCs with both peptibodies showed nearly complete overlap between the cell populations that bound Pep-H6 and Pep-G3 (Fig. 2g) .
Peptibodies deplete MDSCs in vivo and retard tumor growth
We next determined the effect of peptibody treatment on MDSCs in vivo. Intravenous injection of 50 µg Pep-H6 and Pep-G3 completely depleted MDSCs in blood and spleens of EL4 tumor-bearing mice compared with mice given control peptibody (Pep-irrel) or untreated mice (Fig. 3a,b) . Whereas our peptibodies depleted both monocytic and granulocytic MDSC subsets, Gr-1-specific monoclonal antibody (mAb) depleted granulocytic, but not monocytic, MDSCs in both EL4 and EG.7 models. This distinguishing effect of peptibody treatment on monocytic MDSCs was especially apparent when we first subjected the blood to Ficoll sedimentation to remove granulocytes and granulocytic MDSCs ( Fig. 3a-d) . Notably, we observed that peptibody treatment depleted intratumoral MDSCs in both EG.7 ( Fig. 3b-d ) and EL4 ( Supplementary Fig. 3 ) models. Peptibodies also depleted blood and splenic MDSCs in mice bearing A20 lymphomas (Fig. 3e) .
Peptibodies specifically depleted MDSCs in tumor-bearing mice without affecting other proinflammatory cells, including DCs and lymphocytes (T, B and NK cells), which is consistent with their lack of binding to these cells, although Pep-G3 treatment was associated with a minor reduction in NK cell numbers (Fig. 3f) . Although we observed staining of Gr-1 + CD11b + immature myeloid cells from bone marrow with peptibodies, peptibody treatment of tumor-bearing mice did not deplete myeloid precursor cells in this compartment, either (Fig. 3f) . Analysis of other blood cells subsets showed peptibodyassociated depletion of elevated numbers of neutrophils in tumorbearing compared with naive mice, but peptibodies had no effect on numbers of red blood cells or platelets (Supplementary Table 1) .
Finally, to test our hypothesis that MDSC depletion can augment antitumor immunity, we administered peptibodies to EL4-bearing mice every other day to achieve a continuous depletion of systemic MDSCs. Mice treated with Pep-H6 or Pep-G3 alone showed a significant delay in tumor development, measured by tumor size (Fig. 3g ) and tumor mass (Fig. 3h) , compared with untreated or Pep-irreltreated control mice. Whereas both peptibodies clearly inhibited tumor growth in vivo, Gr-1-specific mAb treatment was associated with less consistent inhibition of tumor growth (Fig. 3h) . This effect of peptibody treatment correlated with MDSC depletion at the end of the 2-week treatment ( Supplementary Fig. 4 ).
Cell surface-bound alarmin is a candidate target To explore the target of our peptibody, we developed a strategy to identify peptibody-bound proteins on the surface of MDSCs (Fig. 4a) . We biotinylated surface proteins on sorted Gr-1 + CD11b + MDSCs and subsequently captured them with monomeric avidin after cell lysis. Then, we used Pep-H6 that was immobilized on protein A to immunoprecipitate the surface protein of interest. Proteomic analysis of eluted proteins suggested that S100A9 was the source protein, with sequence coverage above 40% (Fig. 4b) . Consistent with these results, npg t e c h n i c a l r e p o r t s immunoprecipitation studies (without prior biotinylation) showed that eluted proteins from Pep-H6-bound, sorted MDSCs co-migrated with recombinant S100A9 (6× His tagged) and were recognized by S100A9-specific antibodies (Fig. 4c) , but we did not detect any signal when using lysates from MDSCs without peptibody, excluding contamination by intracellular S100A9 (Fig. 4c) . Furthermore, such direct immunoprecipitation of MDSC cell surface proteins with Pep-H6 revealed a protein band that more closely co-migrated with native S100A9 identified by immunoblotting of MDSC total cell lysates (Fig. 4d) . Immunoprecipitation experiments suggested that the peptibody also recognizes S100A8, which is consistent with the formation of S100A9-S100A8 heterodimers (Fig. 4d) . Immunoprecipitation with Pep-G3 also suggested binding to S100A9 and S100A8 proteins (Supplementary Fig. 5 ). These results suggested either cross-reactivity with S100A8 or perhaps recognition of a combinatorial determinant on the S100A9 and S100A8 complex. We then tested our peptibodies in S100A9-deficient mice and observed that peptibodies could bind MDSCs (Fig. 4e) and also partially deplete MDSCs in vivo (Fig. 4f) . Taking these results together, the most likely explanation is that peptibodies are crossreactive for S100A9 and S100A8. This explanation is consistent with the fact that S100A9-deficient mice express S100A8 (ref. 11). Unfortunately, S100A8-deficient mice show an early embryonic lethal phenotype, precluding their analysis for our study. Thus, further characterization of the specificity of our peptibodies for S100 family proteins must await the availability of S100A9 and conditional S100A8 double-knockout mice.
DISCUSSION
We adapted a competitive peptide phage display platform to generate new diagnostic and therapeutic MDSC-specific peptide-Fc fusion (peptibody) reagents. Peptibodies successfully depleted blood and splenic MDSCs, as well as intratumoral MDSCs, in multiple syngeneic tumor models. The superiority of the peptibody therapeutic effects over an available Gr-1-specific mAb was suggested by their ability to deplete both granulocytic and monocytic MDSC subsets (Gr-1-specific a f P e p -ir r e l P e p -G 3 P e p -H 6 P e p -ir r e l P e p -G npg mAb depleted primarily granulocytic MDSCs) and more consistent tumor inhibition in vivo.
To evaluate potential off-target activity of our specific peptibodies, we also assessed potential depletion of normal cell types, including those of myeloid origin. With the exception of transient reduction of blood neutrophils, and possibly monocytes, we did not observe any depletion of DCs, T, B or NK cells or Gr1 + CD11b + immature myeloid precursor cells in the bone marrow in tumor-bearing mice. We also observed that in naive mice, peptibody treatment reduced circulating Gr-1 + CD11b + splenocyte numbers (Supplementary Fig. 6a ) but did not affect immature myeloid cells in the bone marrow ( Supplementary  Fig. 6b) despite binding by peptibody, is unclear. However, our peptibodies were engineered to express mouse IgG2b Fc portion with the goal of enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). One possible explanation is that the effector cells (mature NK cells and macrophages) required for ADCC are present in insufficient numbers in the bone marrow. Finally, peptibody-treated mice suffered no visible adverse effects or constitutional signs of cachexia or ruffled appearance, compared with control naive or tumor-bearing mice, and had otherwise normal blood counts. Altogether, the data suggest limited off-target effects of peptibody treatment. The identification of surface S100A9 and S100A8 as potential peptibody targets validates our protocol as a strategy for cell type-specific surface marker discovery. S100 family calcium-binding proteins are intracellular molecules released to the extracellular milieu by myeloid cells in response to inflammation and function as proinflammatory danger signals (alarmins) 12 . Though there is limited evidence showing that soluble S100A9 binds MDSCs in vitro 13 , it is likely that MDSCs secrete S100A9 in an autocrine feedback mechanism through receptors. The precise nature of the peptibody target remains to be elucidated. Although the epitopes recognized may be derived from S100 proteins, because our protocol used viable cells to screen the peptide library, combinatorial native conformational epitopes composed of the S100-receptor complex would have also been preserved. Given that our peptibody did not bind or deplete DCs, the cell surface receptor for S100A9 and S100A8 on MDSCs may be an as yet unidentified or different from the receptors on DCs, such as RAGE and Toll-like receptor 4. We also acknowledge that it is formally possible that other MDSC-specific targets exist that were not detected by our methods, as biotinylation might mask some epitopes.
Hypothetically, an MDSC-depleting peptibody could cause tumor regression by depleting MDSCs by complement-dependent cytotoxicity or ADCC, inducing apoptosis by blocking the binding of the S100 family protein with its receptor on MDSCs or on tumor cells 14, 15 and interfering with S100-induced survival signals, and inducing direct cytotoxicity against tumor cells 14, 15 . In order to rationally combine peptibody treatment to reverse immune suppression with other immunotherapy strategies, it will also be important to formally demonstrate that inhibition of tumor growth after MDSC depletion is immune mediated. Future studies are needed to investigate these possibilities. Finally, human MDSC targets are needed. Indeed, S100A9 was recently reported on MDSCs isolated from patients with colon cancer 16 . Additional studies are in progress applying the technology platform described de novo to identify new targets on human MDSCs.
METHODS
Methods and any associated references are available in the online version of the paper. Step 1
Step 2
Step 3
Step 4 and Pep-G3 peptibodies with CD11b + Gr-1 + -gated splenic MDSCs from EL4-bearing, S100A9-deficient C57BL/6 mice (n = 3). The data are representative of 2 independent experiments. (f) Frequencies of CD11b + Gr-1 + splenic MDSCs from EL4-bearing, S100A9-deficient C57BL/6 mice (n = 3) after peptibody treatment as in Figure 3a . This experiment was performed once.
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